[go: up one dir, main page]

MXPA02006250A - Butyne diol derivatives. - Google Patents

Butyne diol derivatives.

Info

Publication number
MXPA02006250A
MXPA02006250A MXPA02006250A MXPA02006250A MXPA02006250A MX PA02006250 A MXPA02006250 A MX PA02006250A MX PA02006250 A MXPA02006250 A MX PA02006250A MX PA02006250 A MXPA02006250 A MX PA02006250A MX PA02006250 A MXPA02006250 A MX PA02006250A
Authority
MX
Mexico
Prior art keywords
diol derivatives
butyne diol
compounds
preparation
pharmaceutical compositions
Prior art date
Application number
MXPA02006250A
Other languages
Spanish (es)
Inventor
Walter Fischli
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MXPA02006250A publication Critical patent/MXPA02006250A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to novel butyne diol derivatives ofgeneral formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula (I) and especially their use as endothelin receptor antagonists.
MXPA02006250A 1999-12-22 2000-12-14 Butyne diol derivatives. MXPA02006250A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP9910276 1999-12-22
PCT/EP2000/012743 WO2001046156A1 (en) 1999-12-22 2000-12-14 Butyne diol derivatives

Publications (1)

Publication Number Publication Date
MXPA02006250A true MXPA02006250A (en) 2004-09-06

Family

ID=8167542

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006250A MXPA02006250A (en) 1999-12-22 2000-12-14 Butyne diol derivatives.

Country Status (12)

Country Link
JP (1) JP2003518102A (en)
KR (1) KR20020068373A (en)
CN (1) CN1407973A (en)
AU (1) AU3536701A (en)
BR (1) BR0016241A (en)
CA (1) CA2389479A1 (en)
HU (1) HUP0204168A2 (en)
IL (1) IL149529A0 (en)
MX (1) MXPA02006250A (en)
NO (1) NO20022971L (en)
WO (1) WO2001046156A1 (en)
ZA (1) ZA200203796B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001263850A1 (en) * 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
CN100432070C (en) * 2000-12-18 2008-11-12 埃科特莱茵药品有限公司 Novel sulfonamide compounds and their use as endothelin receptor antagonists
DE602005021641D1 (en) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab NEW DISUBSTITUTED PHENYLPIPERIDINES AND PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION
AR062501A1 (en) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS
MX2010001837A (en) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd DERIVATIVES OF 4-PYRIMIDINASULFAMIDA.
US8916385B2 (en) * 2007-12-13 2014-12-23 Quest Diagnostics Investments, Inc. Methods for detecting estrone by mass spectrometry

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
TW313568B (en) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5962682A (en) * 1994-12-20 1999-10-05 Hoffmann-La Roche Inc. Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
US6083955A (en) * 1995-12-20 2000-07-04 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
WO1998003488A1 (en) * 1996-07-23 1998-01-29 Shionogi & Co., Ltd. Novel pyrimidine compounds and drug compositions
JP4433253B2 (en) * 1998-01-19 2010-03-17 塩野義製薬株式会社 New pyrimidine derivatives

Also Published As

Publication number Publication date
BR0016241A (en) 2002-11-12
HUP0204168A2 (en) 2003-04-28
CN1407973A (en) 2003-04-02
KR20020068373A (en) 2002-08-27
ZA200203796B (en) 2003-10-29
AU3536701A (en) 2001-07-03
NO20022971D0 (en) 2002-06-20
WO2001046156A1 (en) 2001-06-28
IL149529A0 (en) 2002-11-10
NO20022971L (en) 2002-06-20
CA2389479A1 (en) 2001-06-28
JP2003518102A (en) 2003-06-03

Similar Documents

Publication Publication Date Title
MXPA03004780A (en) Novel sulfamides and their use as endothelin receptor antagonists.
IL150986A0 (en) 1,2,3,4,- tetrahydroisoquinoline derivatives
IL155806A0 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
NO20051102L (en) Sulfonylamino-acetic acid derivatives
MXPA05010137A (en) Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists.
WO2002076979A8 (en) 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
IL162851A0 (en) 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
CA2361402A1 (en) Bis-sulfonamides
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
TW200514772A (en) Novel tetrahydropyridine derivatives
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MXPA04001252A (en) Novel benzo-fused heterocycles as endothelin antagonisits.
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
MXPA03000606A (en) Benzofuran derivatives and their use as antibacterial agents.
MY140724A (en) Novel arylethene-sulfonamides
PT1427417E (en) 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents
MXPA02006250A (en) Butyne diol derivatives.
TW200628467A (en) Novel sulfamides
MY138502A (en) Novel alkansulfonamides as endothelin antagonists